{"transactions":[{"id":712912,"issuer":{"id":6146,"kind":"organization","name":"Niagen Bioscience, Inc."},"owners":[{"id":31468,"kind":"person","name":"Lopez Carlos Luis","position":1,"cik":"0002042509","reported_name":"Lopez Carlos Luis","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, General Counsel"}}],"security":"Common Stock","published_at":"2026-07-08T21:18:41.000Z","date":"2026-06-30","kind":"grant","planned":false,"acquired":true,"shares":2314,"price":2.71,"value":6270.94,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares acquired pursuant to the Issuer's Employee Stock Purchase Plan. The acquisition is exempt under Rule 16b-3(c) and 16b-3(d)."}],"balance_after":4565,"source":{"system":"sec-edgar","filing":"0002042509-26-000001","document":"wk-form4_1783545518.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2042509/000204250926000001/wk-form4_1783545518.xml","form_type":"4"}},{"id":712498,"issuer":{"id":6146,"kind":"organization","name":"Niagen Bioscience, Inc."},"owners":[{"id":31396,"kind":"person","name":"Pamir Ozan","position":1,"cik":"0001834681","reported_name":"Pamir Ozan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-07-08T21:17:37.000Z","date":"2026-06-30","kind":"grant","planned":false,"acquired":true,"shares":4255,"price":2.71,"value":11531.05,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares acquired pursuant to the Issuer's Employee Stock Purchase Plan. The acquisition is exempt under Rule 16b-3(c) and 16b-3(d)."}],"balance_after":11627.159,"source":{"system":"sec-edgar","filing":"0001834681-26-000001","document":"wk-form4_1783545455.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1386570/000183468126000001/wk-form4_1783545455.xml","form_type":"4"}},{"id":712555,"issuer":{"id":6146,"kind":"organization","name":"Niagen Bioscience, Inc."},"owners":[{"id":31423,"kind":"person","name":"Fried Robert N","position":1,"cik":"0001417952","reported_name":"Fried Robert N","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-07-08T21:16:50.000Z","date":"2026-06-30","kind":"grant","planned":false,"acquired":true,"shares":1106,"price":2.71,"value":2997.26,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares acquired pursuant to the Issuer's Employee Stock Purchase Plan. The acquisition is exempt under Rule 16b-3(c) and 16b-3(d)."}],"balance_after":1060087,"source":{"system":"sec-edgar","filing":"0001417952-26-000002","document":"wk-form4_1783545408.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1417952/000141795226000002/wk-form4_1783545408.xml","form_type":"4"}},{"id":725521,"issuer":{"id":6146,"kind":"organization","name":"Niagen Bioscience, Inc."},"owners":[{"id":35159,"kind":"person","name":"YU Wing Tak Wendy","position":1,"cik":"0001713918","reported_name":"YU Wing Tak Wendy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-26T22:03:20.000Z","date":"2026-06-24","kind":"grant","planned":false,"acquired":true,"shares":31746,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Option vests 100% on June 24, 2027."}],"balance_after":31746,"derivative":{"exercise_price":3.45,"exercise_date":"2027-06-24","expiration_date":"2036-06-23","underlying":"Common Stock","underlying_shares":31746},"source":{"system":"sec-edgar","filing":"0001713918-26-000001","document":"wk-form4_1782511398.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1713918/000171391826000001/wk-form4_1782511398.xml","form_type":"4"}},{"id":725658,"issuer":{"id":6146,"kind":"organization","name":"Niagen Bioscience, Inc."},"owners":[{"id":35199,"kind":"person","name":"Ng Wang Yu Gary","position":1,"cik":"0001896252","reported_name":"Ng Wang Yu Gary","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-26T22:02:14.000Z","date":"2026-06-24","kind":"grant","planned":false,"acquired":true,"shares":31746,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Option vests 100% on June 24, 2027."}],"balance_after":31746,"derivative":{"exercise_price":3.45,"exercise_date":"2027-06-24","expiration_date":"2036-06-23","underlying":"Common Stock","underlying_shares":31746},"source":{"system":"sec-edgar","filing":"0001896252-26-000001","document":"wk-form4_1782511331.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1896252/000189625226000001/wk-form4_1782511331.xml","form_type":"4"}},{"id":725661,"issuer":{"id":6146,"kind":"organization","name":"Niagen Bioscience, Inc."},"owners":[{"id":35201,"kind":"person","name":"Cohen Ann","position":1,"cik":"0001923843","reported_name":"Cohen Ann","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-26T22:01:21.000Z","date":"2026-06-24","kind":"grant","planned":false,"acquired":true,"shares":31746,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Option vests 100% on June 24, 2027."}],"balance_after":31746,"derivative":{"exercise_price":3.45,"exercise_date":"2027-06-24","expiration_date":"2036-06-23","underlying":"Common Stock","underlying_shares":31746},"source":{"system":"sec-edgar","filing":"0001923843-26-000001","document":"wk-form4_1782511278.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1923843/000192384326000001/wk-form4_1782511278.xml","form_type":"4"}},{"id":725286,"issuer":{"id":6146,"kind":"organization","name":"Niagen Bioscience, Inc."},"owners":[{"id":30735,"kind":"person","name":"Patrick Kristin","position":1,"cik":"0001769529","reported_name":"Patrick Kristin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-26T21:57:25.000Z","date":"2026-06-24","kind":"grant","planned":false,"acquired":true,"shares":31746,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Option vests 100% on June 24, 2027."}],"balance_after":31746,"derivative":{"exercise_price":3.45,"exercise_date":"2027-06-24","expiration_date":"2036-06-23","underlying":"Common Stock","underlying_shares":31746},"source":{"system":"sec-edgar","filing":"0001769529-26-000003","document":"wk-form4_1782511043.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1386570/000176952926000003/wk-form4_1782511043.xml","form_type":"4"}},{"id":725664,"issuer":{"id":6146,"kind":"organization","name":"Niagen Bioscience, Inc."},"owners":[{"id":35203,"kind":"person","name":"Shahbazi Hamed","position":1,"cik":"0001942711","reported_name":"Shahbazi Hamed","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-26T21:56:44.000Z","date":"2026-06-24","kind":"grant","planned":false,"acquired":true,"shares":31746,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Option vests 100% on June 24, 2027."}],"balance_after":31746,"derivative":{"exercise_price":3.45,"exercise_date":"2027-06-24","expiration_date":"2036-06-23","underlying":"Common Stock","underlying_shares":31746},"source":{"system":"sec-edgar","filing":"0001942711-26-000001","document":"wk-form4_1782511002.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1942711/000194271126000001/wk-form4_1782511002.xml","form_type":"4"}},{"id":725287,"issuer":{"id":6146,"kind":"organization","name":"Niagen Bioscience, Inc."},"owners":[{"id":25378,"kind":"person","name":"Rubin Steven D","position":1,"cik":"0001381874","reported_name":"Rubin Steven D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-26T21:55:57.000Z","date":"2026-06-24","kind":"grant","planned":false,"acquired":true,"shares":31746,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Option vests 100% on June 24, 2027."}],"balance_after":31746,"derivative":{"exercise_price":3.45,"exercise_date":"2027-06-24","expiration_date":"2036-06-23","underlying":"Common Stock","underlying_shares":31746},"source":{"system":"sec-edgar","filing":"0001381874-26-000001","document":"wk-form4_1782510955.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1381874/000138187426000001/wk-form4_1782510955.xml","form_type":"4"}},{"id":725419,"issuer":{"id":6146,"kind":"organization","name":"Niagen Bioscience, Inc."},"owners":[{"id":35127,"kind":"person","name":"Jaksch Frank L Jr","position":1,"cik":"0001437237","reported_name":"Jaksch Frank L Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-26T21:54:46.000Z","date":"2026-06-24","kind":"grant","planned":false,"acquired":true,"shares":31746,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Option vests 100% on June 24, 2027."}],"balance_after":31746,"derivative":{"exercise_price":3.45,"exercise_date":"2027-06-24","expiration_date":"2036-06-23","underlying":"Common Stock","underlying_shares":31746},"source":{"system":"sec-edgar","filing":"0001437237-26-000001","document":"wk-form4_1782510883.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1437237/000143723726000001/wk-form4_1782510883.xml","form_type":"4"}},{"id":800005,"issuer":{"id":6146,"kind":"organization","name":"Niagen Bioscience, Inc."},"owners":[{"id":31423,"kind":"person","name":"Fried Robert N","position":1,"cik":"0001417952","reported_name":"Fried Robert N","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Options (right to buy)","published_at":"2026-04-27T12:33:59.000Z","date":"2026-04-24","kind":"exercise","planned":false,"acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":2.61,"exercise_date":"2017-11-16","expiration_date":"2026-11-15","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001417952-26-000001","document":"wk-form4_1777293236.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1417952/000141795226000001/wk-form4_1777293236.xml","form_type":"4"}},{"id":800004,"issuer":{"id":6146,"kind":"organization","name":"Niagen Bioscience, Inc."},"owners":[{"id":31423,"kind":"person","name":"Fried Robert N","position":1,"cik":"0001417952","reported_name":"Fried Robert N","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-04-27T12:33:59.000Z","date":"2026-04-24","kind":"exercise","planned":false,"acquired":true,"shares":20000,"price":2.61,"value":52200.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Reporting Person exercised the stock options reported on this Form 4 in advance of their expiration on November 15, 2026, paying the exercise price with cash, and has not sold any of the shares received upon exercise."}],"balance_after":1058981,"source":{"system":"sec-edgar","filing":"0001417952-26-000001","document":"wk-form4_1777293236.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1417952/000141795226000001/wk-form4_1777293236.xml","form_type":"4"}},{"id":885456,"issuer":{"id":6146,"kind":"organization","name":"Niagen Bioscience, Inc."},"owners":[{"id":31468,"kind":"person","name":"Lopez Carlos Luis","position":1,"cik":"0002042509","reported_name":"Lopez Carlos Luis","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, General Counsel"}}],"security":"Employee Stock Options (right to buy)","published_at":"2026-02-24T21:47:28.000Z","date":"2026-02-19","kind":"grant","planned":false,"acquired":true,"shares":41420,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-fourth of the shares subject to the option shall vest on each anniversary of the grant date."}],"balance_after":41420,"derivative":{"exercise_price":4.94,"exercise_date":"2027-02-19","expiration_date":"2036-02-18","underlying":"Common Stock","underlying_shares":41420},"source":{"system":"sec-edgar","filing":"0001628280-26-011162","document":"wk-form4_1771969645.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2042509/000162828026011162/wk-form4_1771969645.xml","form_type":"4"}},{"id":884196,"issuer":{"id":6146,"kind":"organization","name":"Niagen Bioscience, Inc."},"owners":[{"id":31396,"kind":"person","name":"Pamir Ozan","position":1,"cik":"0001834681","reported_name":"Pamir Ozan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Options (right to buy)","published_at":"2026-02-24T21:46:19.000Z","date":"2026-02-19","kind":"grant","planned":false,"acquired":true,"shares":62131,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-fourth of the shares subject to the option shall vest on each anniversary of the grant date."}],"balance_after":62131,"derivative":{"exercise_price":4.94,"exercise_date":"2027-02-19","expiration_date":"2036-02-18","underlying":"Common Stock","underlying_shares":62131},"source":{"system":"sec-edgar","filing":"0001628280-26-011160","document":"wk-form4_1771969576.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1386570/000162828026011160/wk-form4_1771969576.xml","form_type":"4"}},{"id":884524,"issuer":{"id":6146,"kind":"organization","name":"Niagen Bioscience, Inc."},"owners":[{"id":31423,"kind":"person","name":"Fried Robert N","position":1,"cik":"0001417952","reported_name":"Fried Robert N","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Options (right to buy)","published_at":"2026-02-24T21:44:59.000Z","date":"2026-02-19","kind":"grant","planned":false,"acquired":true,"shares":503937,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-fourth of the shares subject to the option shall vest on each anniversary of the grant date."}],"balance_after":503937,"derivative":{"exercise_price":4.94,"exercise_date":"2027-02-19","expiration_date":"2036-02-18","underlying":"Common Stock","underlying_shares":503937},"source":{"system":"sec-edgar","filing":"0001628280-26-011159","document":"wk-form4_1771969496.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1417952/000162828026011159/wk-form4_1771969496.xml","form_type":"4"}},{"id":997559,"issuer":{"id":6146,"kind":"organization","name":"Niagen Bioscience, Inc."},"owners":[{"id":31396,"kind":"person","name":"Pamir Ozan","position":1,"cik":"0001834681","reported_name":"Pamir Ozan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-11-17T13:23:28.000Z","date":"2025-11-14","kind":"purchase","planned":false,"acquired":true,"shares":2220.443,"price":6.85,"value":15210.03455,"ownership":{"direct":false,"nature":"The reported securities are held by the reporting person's spouse."},"balance_after":2220.443,"source":{"system":"sec-edgar","filing":"0001834681-25-000005","document":"wk-form4_1763385804.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1386570/000183468125000005/wk-form4_1763385804.xml","form_type":"4"}},{"id":997558,"issuer":{"id":6146,"kind":"organization","name":"Niagen Bioscience, Inc."},"owners":[{"id":31396,"kind":"person","name":"Pamir Ozan","position":1,"cik":"0001834681","reported_name":"Pamir Ozan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-11-17T13:23:28.000Z","date":"2025-11-14","kind":"purchase","planned":false,"acquired":true,"shares":4464.962,"price":6.81,"value":30406.39122,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The weighted average purchase price for the transaction reported was $6.81, and the range of prices were between $6.7975 and $6.82, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased at each separate price within the range above will be provided."}],"balance_after":7372.159,"source":{"system":"sec-edgar","filing":"0001834681-25-000005","document":"wk-form4_1763385804.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1386570/000183468125000005/wk-form4_1763385804.xml","form_type":"4"}},{"id":1092775,"issuer":{"id":6146,"kind":"organization","name":"Niagen Bioscience, Inc."},"owners":[{"id":35203,"kind":"person","name":"Shahbazi Hamed","position":1,"cik":"0001942711","reported_name":"Shahbazi Hamed","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-07-03T14:42:17.000Z","date":"2025-06-24","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Option vests 100% on June 24, 2026."}],"balance_after":20000,"derivative":{"exercise_price":14.13,"exercise_date":"2026-06-24","expiration_date":"2035-06-23","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001628280-25-034160","document":"wk-form4_1751553733.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1942711/000162828025034160/wk-form4_1751553733.xml","form_type":"4"}},{"id":1101081,"issuer":{"id":6146,"kind":"organization","name":"Niagen Bioscience, Inc."},"owners":[{"id":35159,"kind":"person","name":"YU Wing Tak Wendy","position":1,"cik":"0001713918","reported_name":"YU Wing Tak Wendy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-26T21:30:41.000Z","date":"2025-06-24","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Option vests 100% on June 24, 2026."}],"balance_after":20000,"derivative":{"exercise_price":14.13,"exercise_date":"2026-06-24","expiration_date":"2035-06-23","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001628280-25-033150","document":"wk-form4_1750973437.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1713918/000162828025033150/wk-form4_1750973437.xml","form_type":"4"}},{"id":1100894,"issuer":{"id":6146,"kind":"organization","name":"Niagen Bioscience, Inc."},"owners":[{"id":30735,"kind":"person","name":"Patrick Kristin","position":1,"cik":"0001769529","reported_name":"Patrick Kristin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-26T21:29:03.000Z","date":"2025-06-24","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Option vests 100% on June 24, 2026."}],"balance_after":20000,"derivative":{"exercise_price":14.13,"exercise_date":"2026-06-24","expiration_date":"2035-06-23","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001628280-25-033148","document":"wk-form4_1750973339.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1386570/000162828025033148/wk-form4_1750973339.xml","form_type":"4"}},{"id":1101544,"issuer":{"id":6146,"kind":"organization","name":"Niagen Bioscience, Inc."},"owners":[{"id":25378,"kind":"person","name":"Rubin Steven D","position":1,"cik":"0001381874","reported_name":"Rubin Steven D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-26T00:29:27.000Z","date":"2025-06-24","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Option vests 100% on June 24, 2026."}],"balance_after":20000,"derivative":{"exercise_price":14.13,"exercise_date":"2026-06-24","expiration_date":"2035-06-23","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001628280-25-033063","document":"wk-form4_1750897763.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1381874/000162828025033063/wk-form4_1750897763.xml","form_type":"4"}},{"id":1101793,"issuer":{"id":6146,"kind":"organization","name":"Niagen Bioscience, Inc."},"owners":[{"id":35199,"kind":"person","name":"Ng Wang Yu Gary","position":1,"cik":"0001896252","reported_name":"Ng Wang Yu Gary","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-26T00:28:02.000Z","date":"2025-06-24","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Option vests 100% on June 24, 2026."}],"balance_after":20000,"derivative":{"exercise_price":14.13,"exercise_date":"2026-06-24","expiration_date":"2035-06-23","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001628280-25-033061","document":"wk-form4_1750897677.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1896252/000162828025033061/wk-form4_1750897677.xml","form_type":"4"}},{"id":1101798,"issuer":{"id":6146,"kind":"organization","name":"Niagen Bioscience, Inc."},"owners":[{"id":35201,"kind":"person","name":"Cohen Ann","position":1,"cik":"0001923843","reported_name":"Cohen Ann","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-26T00:25:19.000Z","date":"2025-06-24","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Option vests 100% on June 24, 2026."}],"balance_after":20000,"derivative":{"exercise_price":14.13,"exercise_date":"2026-06-24","expiration_date":"2035-06-23","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001628280-25-033059","document":"wk-form4_1750897515.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1923843/000162828025033059/wk-form4_1750897515.xml","form_type":"4"}},{"id":1101635,"issuer":{"id":6146,"kind":"organization","name":"Niagen Bioscience, Inc."},"owners":[{"id":35127,"kind":"person","name":"Jaksch Frank L Jr","position":1,"cik":"0001437237","reported_name":"Jaksch Frank L Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-26T00:23:40.000Z","date":"2025-06-24","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Option vests 100% on June 24, 2026."}],"balance_after":20000,"derivative":{"exercise_price":14.13,"exercise_date":"2026-06-24","expiration_date":"2035-06-23","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001628280-25-033057","document":"wk-form4_1750897416.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1437237/000162828025033057/wk-form4_1750897416.xml","form_type":"4"}},{"id":1174634,"issuer":{"id":6146,"kind":"organization","name":"Niagen Bioscience, Inc."},"owners":[{"id":31423,"kind":"person","name":"Fried Robert N","position":1,"cik":"0001417952","reported_name":"Fried Robert N","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Options (right to buy)","published_at":"2025-04-09T23:52:42.000Z","date":"2025-04-09","kind":"exercise","planned":false,"acquired":false,"shares":66667,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":3.3,"exercise_date":"2015-08-30","expiration_date":"2025-07-29","underlying":"Common Stock","underlying_shares":66667},"source":{"system":"sec-edgar","filing":"0001628280-25-017223","document":"wk-form4_1744242755.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1417952/000162828025017223/wk-form4_1744242755.xml","form_type":"4"}},{"id":1174633,"issuer":{"id":6146,"kind":"organization","name":"Niagen Bioscience, Inc."},"owners":[{"id":31423,"kind":"person","name":"Fried Robert N","position":1,"cik":"0001417952","reported_name":"Fried Robert N","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-04-09T23:52:42.000Z","date":"2025-04-09","kind":"exercise","planned":false,"acquired":true,"shares":66667,"price":3.3,"value":220001.1,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The Reporting Person exercised the stock options reported on this Form 4 in advance of their expiration on July 29, 2025, paying the exercise price with cash, and has not sold any of the shares received upon exercise."}],"balance_after":1038981,"source":{"system":"sec-edgar","filing":"0001628280-25-017223","document":"wk-form4_1744242755.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1417952/000162828025017223/wk-form4_1744242755.xml","form_type":"4"}},{"id":1215513,"issuer":{"id":6146,"kind":"organization","name":"Niagen Bioscience, Inc."},"owners":[{"id":31468,"kind":"person","name":"Lopez Carlos Luis","position":1,"cik":"0002042509","reported_name":"Lopez Carlos Luis","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, General Counsel"}}],"security":"Common Stock","published_at":"2025-03-10T12:11:11.000Z","date":"2025-03-07","kind":"purchase","planned":false,"acquired":true,"shares":273,"price":7.86,"value":2145.78,"ownership":{"direct":true},"balance_after":2251,"source":{"system":"sec-edgar","filing":"0001628280-25-011466","document":"wk-form4_1741608665.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2042509/000162828025011466/wk-form4_1741608665.xml","form_type":"4"}},{"id":1240506,"issuer":{"id":6146,"kind":"organization","name":"Niagen Bioscience, Inc."},"owners":[{"id":31423,"kind":"person","name":"Fried Robert N","position":1,"cik":"0001417952","reported_name":"Fried Robert N","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Performance Stock Unit","published_at":"2025-02-27T21:42:35.000Z","date":"2025-02-25","kind":"grant","planned":false,"acquired":true,"shares":1518600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Performance Stock Unit (\"PSU\") represents a contingent right to receive one share of the company's common stock when vested. The PSUs vest incrementally upon the Company's common stock achieving specified price per share performance goals and continued employment prior to February 25, 2032, and subject to a change in control."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each Performance Stock Unit (\"PSU\") represents a contingent right to receive one share of the company's common stock when vested. The PSUs vest incrementally upon the Company's common stock achieving specified price per share performance goals and continued employment prior to February 25, 2032, and subject to a change in control."}],"balance_after":1518600,"derivative":{"expiration_date":"2032-02-25","underlying":"Common Stock","underlying_shares":1518600},"source":{"system":"sec-edgar","filing":"0001628280-25-008721","document":"wk-form4_1740692548.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1417952/000162828025008721/wk-form4_1740692548.xml","form_type":"4"}},{"id":1267773,"issuer":{"id":6146,"kind":"organization","name":"Niagen Bioscience, Inc."},"owners":[{"id":31468,"kind":"person","name":"Lopez Carlos Luis","position":1,"cik":"0002042509","reported_name":"Lopez Carlos Luis","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, General Counsel"}}],"security":"Employee Stock Options (right to buy)","published_at":"2025-02-14T23:19:33.000Z","date":"2025-02-12","kind":"grant","planned":false,"acquired":true,"shares":19691,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-third of the shares subject to the option shall vest on February 12, 2026 and the remaining shares subject to the option shall vest in a series of 24 equal monthly installments thereafter."}],"balance_after":19691,"derivative":{"exercise_price":5.48,"exercise_date":"2026-02-12","expiration_date":"2035-02-11","underlying":"Common Stock","underlying_shares":19691},"source":{"system":"sec-edgar","filing":"0001628280-25-005858","document":"wk-form4_1739575167.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2042509/000162828025005858/wk-form4_1739575167.xml","form_type":"4"}},{"id":1266846,"issuer":{"id":6146,"kind":"organization","name":"Niagen Bioscience, Inc."},"owners":[{"id":31396,"kind":"person","name":"Pamir Ozan","position":1,"cik":"0001834681","reported_name":"Pamir Ozan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Options (right to buy)","published_at":"2025-02-14T23:18:14.000Z","date":"2025-02-12","kind":"grant","planned":false,"acquired":true,"shares":17230,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-third of the shares subject to the option shall vest on February 12, 2026 and the remaining shares subject to the option shall vest in a series of 24 equal monthly installments thereafter."}],"balance_after":17230,"derivative":{"exercise_price":5.48,"exercise_date":"2026-02-12","expiration_date":"2035-02-11","underlying":"Common Stock","underlying_shares":17230},"source":{"system":"sec-edgar","filing":"0001628280-25-005854","document":"wk-form4_1739575087.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1386570/000162828025005854/wk-form4_1739575087.xml","form_type":"4"}},{"id":1267043,"issuer":{"id":6146,"kind":"organization","name":"Niagen Bioscience, Inc."},"owners":[{"id":31423,"kind":"person","name":"Fried Robert N","position":1,"cik":"0001417952","reported_name":"Fried Robert N","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Options (right to buy)","published_at":"2025-02-14T23:17:07.000Z","date":"2025-02-12","kind":"grant","planned":false,"acquired":true,"shares":492278,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-third of the shares subject to the option shall vest on February 12, 2026 and the remaining shares subject to the option shall vest in a series of 24 equal monthly installments thereafter."}],"balance_after":492278,"derivative":{"exercise_price":5.48,"exercise_date":"2026-02-12","expiration_date":"2035-02-11","underlying":"Common Stock","underlying_shares":492278},"source":{"system":"sec-edgar","filing":"0001628280-25-005851","document":"wk-form4_1739575019.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1417952/000162828025005851/wk-form4_1739575019.xml","form_type":"4"}},{"id":1332222,"issuer":{"id":6146,"kind":"organization","name":"Niagen Bioscience, Inc."},"owners":[{"id":35127,"kind":"person","name":"Jaksch Frank L Jr","position":1,"cik":"0001437237","reported_name":"Jaksch Frank L Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Options (right to buy)","published_at":"2024-12-14T00:12:16.000Z","date":"2024-12-13","kind":"exercise","planned":false,"acquired":false,"shares":50001,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":3.66,"exercise_date":"2016-07-06","expiration_date":"2025-07-05","underlying":"Common Stock","underlying_shares":50001},"source":{"system":"sec-edgar","filing":"0001628280-24-051264","document":"wk-form4_1734135129.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1437237/000162828024051264/wk-form4_1734135129.xml","form_type":"4"}},{"id":1332221,"issuer":{"id":6146,"kind":"organization","name":"Niagen Bioscience, Inc."},"owners":[{"id":35127,"kind":"person","name":"Jaksch Frank L Jr","position":1,"cik":"0001437237","reported_name":"Jaksch Frank L Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-12-14T00:12:16.000Z","date":"2024-12-13","kind":"sale","planned":false,"acquired":false,"shares":37161,"price":6.1881,"value":229955.9841,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The weighted average sale price for the transaction reported was $6.1881, and the range of prices were between $6.13 and $6.285. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"The sale of shares was solely to cover the exercise cost and associated taxes for the exercise of the options which were scheduled to expire on July 5, 2025.  As a result of the exercise of the options, the Reporting Person will own 12,840 more shares."}],"balance_after":244179,"source":{"system":"sec-edgar","filing":"0001628280-24-051264","document":"wk-form4_1734135129.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1437237/000162828024051264/wk-form4_1734135129.xml","form_type":"4"}},{"id":1332220,"issuer":{"id":6146,"kind":"organization","name":"Niagen Bioscience, Inc."},"owners":[{"id":35127,"kind":"person","name":"Jaksch Frank L Jr","position":1,"cik":"0001437237","reported_name":"Jaksch Frank L Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-12-14T00:12:16.000Z","date":"2024-12-13","kind":"exercise","planned":false,"acquired":true,"shares":50001,"price":3.66,"value":183003.66,"ownership":{"direct":true},"balance_after":281340,"source":{"system":"sec-edgar","filing":"0001628280-24-051264","document":"wk-form4_1734135129.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1437237/000162828024051264/wk-form4_1734135129.xml","form_type":"4"}},{"id":1352393,"issuer":{"id":6146,"kind":"organization","name":"Niagen Bioscience, Inc."},"owners":[{"id":31396,"kind":"person","name":"Pamir Ozan","position":1,"cik":"0001834681","reported_name":"Pamir Ozan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-11-25T12:28:56.000Z","date":"2024-11-22","kind":"purchase","planned":false,"acquired":true,"shares":2907.197,"price":7.36,"value":21396.96992,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The weighted average purchase price for the transaction reported was $7.36, and the range of prices were between $7.345 and $7.36, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased at each separate price within the range above will be provided."}],"balance_after":2907.197,"source":{"system":"sec-edgar","filing":"0001628280-24-049079","document":"wk-form4_1732537730.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1386570/000162828024049079/wk-form4_1732537730.xml","form_type":"4"}},{"id":1382326,"issuer":{"id":6146,"kind":"organization","name":"Niagen Bioscience, Inc."},"owners":[{"id":31396,"kind":"person","name":"Pamir Ozan","position":1,"cik":"0001834681","reported_name":"Pamir Ozan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Options (right to buy)","published_at":"2024-10-23T21:04:08.000Z","date":"2024-10-21","kind":"grant","planned":false,"acquired":true,"shares":146544,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-third of the shares subject to the option shall vest on October 21, 2025 and the remaining shares subject to the option shall vest in a series of 24 equal monthly installments thereafter."}],"balance_after":146544,"derivative":{"exercise_price":3.46,"exercise_date":"2025-10-21","expiration_date":"2034-10-20","underlying":"Common Stock","underlying_shares":146544},"source":{"system":"sec-edgar","filing":"0001628280-24-043462","document":"wk-form4_1729717442.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1386570/000162828024043462/wk-form4_1729717442.xml","form_type":"4"}},{"id":1423066,"issuer":{"id":6146,"kind":"organization","name":"Niagen Bioscience, Inc."},"owners":[{"id":30735,"kind":"person","name":"Patrick Kristin","position":1,"cik":"0001769529","reported_name":"Patrick Kristin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-08-26T23:06:28.000Z","date":"2024-08-23","kind":"exercise","planned":false,"acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":1.67,"exercise_date":"2024-06-15","expiration_date":"2033-06-14","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001628280-24-038470","document":"wk-form4_1724713582.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1386570/000162828024038470/wk-form4_1724713582.xml","form_type":"4"}},{"id":1423065,"issuer":{"id":6146,"kind":"organization","name":"Niagen Bioscience, Inc."},"owners":[{"id":30735,"kind":"person","name":"Patrick Kristin","position":1,"cik":"0001769529","reported_name":"Patrick Kristin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-08-26T23:06:28.000Z","date":"2024-08-23","kind":"exercise","planned":false,"acquired":false,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":17000,"derivative":{"exercise_price":1.64,"exercise_date":"2023-06-16","expiration_date":"2032-06-15","underlying":"Common Stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0001628280-24-038470","document":"wk-form4_1724713582.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1386570/000162828024038470/wk-form4_1724713582.xml","form_type":"4"}},{"id":1423064,"issuer":{"id":6146,"kind":"organization","name":"Niagen Bioscience, Inc."},"owners":[{"id":30735,"kind":"person","name":"Patrick Kristin","position":1,"cik":"0001769529","reported_name":"Patrick Kristin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-08-26T23:06:28.000Z","date":"2024-08-23","kind":"sale","planned":false,"acquired":false,"shares":23000,"price":3.57,"value":82110.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The weighted average sale price for the transaction reported was $3.57, and the range of prices were between $3.52 and $3.64. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001628280-24-038470","document":"wk-form4_1724713582.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1386570/000162828024038470/wk-form4_1724713582.xml","form_type":"4"}},{"id":1423063,"issuer":{"id":6146,"kind":"organization","name":"Niagen Bioscience, Inc."},"owners":[{"id":30735,"kind":"person","name":"Patrick Kristin","position":1,"cik":"0001769529","reported_name":"Patrick Kristin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-08-26T23:06:28.000Z","date":"2024-08-23","kind":"exercise","planned":false,"acquired":true,"shares":20000,"price":1.67,"value":33400.0,"ownership":{"direct":true},"balance_after":23000,"source":{"system":"sec-edgar","filing":"0001628280-24-038470","document":"wk-form4_1724713582.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1386570/000162828024038470/wk-form4_1724713582.xml","form_type":"4"}},{"id":1423062,"issuer":{"id":6146,"kind":"organization","name":"Niagen Bioscience, Inc."},"owners":[{"id":30735,"kind":"person","name":"Patrick Kristin","position":1,"cik":"0001769529","reported_name":"Patrick Kristin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-08-26T23:06:28.000Z","date":"2024-08-23","kind":"exercise","planned":false,"acquired":true,"shares":3000,"price":1.64,"value":4920.0,"ownership":{"direct":true},"balance_after":3000,"source":{"system":"sec-edgar","filing":"0001628280-24-038470","document":"wk-form4_1724713582.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1386570/000162828024038470/wk-form4_1724713582.xml","form_type":"4"}},{"id":1426557,"issuer":{"id":6146,"kind":"organization","name":"Niagen Bioscience, Inc."},"owners":[{"id":88120,"kind":"person","name":"Li Ka Shing","position":1,"cik":"0001686621","reported_name":"Li Ka Shing","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":88121,"kind":"organization","name":"Prime Tech Global Ltd","position":2,"cik":"0001706084","reported_name":"Prime Tech Global Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":88122,"kind":"organization","name":"Mayspin Management Ltd","position":3,"cik":"0001706083","reported_name":"Mayspin Management Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-08-21T06:15:05.000Z","date":"2024-08-20","kind":"sale","planned":false,"acquired":false,"shares":11408715,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On August 20, 2024, Prime Tech Global Limited, a British Virgin Islands corporation (\"Prime Tech\") and Alpha Mount International Limited, a British Virgin Islands corporation (\"Alpha\") entered into a securities purchase agreement with Brilliant Dynasty Limited, a British Virgin Islands corporation (\"Brilliant Dynasty\"), to sell all of the share capital of Champion River Ventures Limited, a British Virgin Islands corporation (\"Champion River\"), Winsave Resources Limited, a British Virgin Islands corporation (\"Winsave\") and Radiant Treasure Limited, a British Virgin Islands corporation (\"Radiant\") to Brilliant Dynasty, for an aggregate consideration of $32,058,489.15. At time of entry into the securities purchase agreement, Champion River, Winsave and Radiant beneficially owned 7,940,937, 3,088,433 and 379,345 shares of common stock  of the Issuer, respectively."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 20, 2024, Prime Tech Global Limited, a British Virgin Islands corporation (\"Prime Tech\") and Alpha Mount International Limited, a British Virgin Islands corporation (\"Alpha\") entered into a securities purchase agreement with Brilliant Dynasty Limited, a British Virgin Islands corporation (\"Brilliant Dynasty\"), to sell all of the share capital of Champion River Ventures Limited, a British Virgin Islands corporation (\"Champion River\"), Winsave Resources Limited, a British Virgin Islands corporation (\"Winsave\") and Radiant Treasure Limited, a British Virgin Islands corporation (\"Radiant\") to Brilliant Dynasty, for an aggregate consideration of $32,058,489.15. At time of entry into the securities purchase agreement, Champion River, Winsave and Radiant beneficially owned 7,940,937, 3,088,433 and 379,345 shares of common stock  of the Issuer, respectively."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The sole shareholder of Prime Tech is Mayspin Management Limited (\"Mayspin\"), and the sole shareholder of Mayspin is Li Ka Shing. The sole shareholder of Alpha is Apex Dynasty Limited, a British Virgin Islands corporation (\"Apex\"), and the sole shareholder of Apex is Li Ka Shing."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The sole shareholder of Prime Tech is Mayspin Management Limited (\"Mayspin\"), and the sole shareholder of Mayspin is Li Ka Shing. The sole shareholder of Alpha is Apex Dynasty Limited, a British Virgin Islands corporation (\"Apex\"), and the sole shareholder of Apex is Li Ka Shing."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The sole shareholder of Prime Tech is Mayspin Management Limited (\"Mayspin\"), and the sole shareholder of Mayspin is Li Ka Shing. The sole shareholder of Alpha is Apex Dynasty Limited, a British Virgin Islands corporation (\"Apex\"), and the sole shareholder of Apex is Li Ka Shing."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-24-099383","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1686621/000095017024099383/ownership.xml","form_type":"4"}},{"id":1426693,"issuer":{"id":6146,"kind":"organization","name":"Niagen Bioscience, Inc."},"owners":[{"id":88129,"kind":"person","name":"Chau Hoi Shuen Solina Holly","position":1,"cik":"0001687026","reported_name":"Chau Hoi Shuen Solina Holly","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":88130,"kind":"organization","name":"Pioneer Step Holdings Ltd","position":2,"cik":"0001705335","reported_name":"Pioneer Step Holdings Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":88131,"kind":"organization","name":"Dvorak International Ltd","position":3,"cik":"0001796851","reported_name":"Dvorak International Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":88132,"kind":"organization","name":"Skyinvest Associates Ltd","position":4,"cik":"0001956280","reported_name":"Skyinvest Associates Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":88133,"kind":"organization","name":"Elgar International Ltd","position":5,"cik":"0002032924","reported_name":"Elgar International Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":88134,"kind":"organization","name":"Brilliant Dynasty Ltd","position":6,"cik":"0002032925","reported_name":"Brilliant Dynasty Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":88135,"kind":"organization","name":"Champion River Ventures Ltd","position":7,"cik":"0001705321","reported_name":"Champion River Ventures Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":88136,"kind":"organization","name":"Winsave Resources Ltd","position":8,"cik":"0001811501","reported_name":"Winsave Resources Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":88137,"kind":"organization","name":"Radiant Treasure Ltd","position":9,"cik":"0001944668","reported_name":"Radiant Treasure Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-08-21T06:15:03.000Z","date":"2024-08-20","kind":"purchase","planned":false,"acquired":true,"shares":11408715,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On August 20, 2024, Brilliant Dynasty Limited, a British Virgin Islands corporation (\"Brilliant Dynasty\") entered into a securities purchase agreement with Prime Tech Global Limited, a British Virgin Islands corporation (\"Prime Tech\") and Alpha Mount International Limited, a British Virgin Islands corporation (\"Alpha\") to purchase all of the share capital of Champion River Ventures Limited, a British Virgin Islands corporation (\"Champion River\"), Winsave Resources Limited, a British Virgin Islands corporation (\"Winsave\"), and Radiant Treasure Limited, a British Virgin Islands corporation (\"Radiant\") from Prime Tech and Alpha, for an aggregate consideration of $32,058,489.15 (the \"August 2024 Transaction\"). At time of entry into the securities purchase agreement, Champion River, Winsave and Radiant beneficially owned 7,940,937, 3,088,433 and 379,345 shares of common stock  of the Issuer, respectively."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 20, 2024, Brilliant Dynasty Limited, a British Virgin Islands corporation (\"Brilliant Dynasty\") entered into a securities purchase agreement with Prime Tech Global Limited, a British Virgin Islands corporation (\"Prime Tech\") and Alpha Mount International Limited, a British Virgin Islands corporation (\"Alpha\") to purchase all of the share capital of Champion River Ventures Limited, a British Virgin Islands corporation (\"Champion River\"), Winsave Resources Limited, a British Virgin Islands corporation (\"Winsave\"), and Radiant Treasure Limited, a British Virgin Islands corporation (\"Radiant\") from Prime Tech and Alpha, for an aggregate consideration of $32,058,489.15 (the \"August 2024 Transaction\"). At time of entry into the securities purchase agreement, Champion River, Winsave and Radiant beneficially owned 7,940,937, 3,088,433 and 379,345 shares of common stock  of the Issuer, respectively."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Of the total shares beneficially owned following the reported transaction (i) 6,917,783 shares of the Issuer's common stock are directly beneficially owned by Pioneer Step Holdings Limited, a British Virgin Islands corporation (\"Pioneer Step\"), (ii) 420,000 shares of the Issuer's common stock are directly beneficially owned by Dvorak International Limited (\"Dvorak International\"), (iii) 547,858 shares of the Issuer's common stock are directly beneficially owned by Skyinvest Associates Limited (\"Skyinvest Associates\"), (iv) 7,940,937 shares of the Issuer's common stock are directly beneficially owned by Champion River, (v) 3,088,433 shares of the Issuer's common stock are directly beneficially owned by Winsave, and (vi) 379,345 shares of the Issuer's common stock are directly beneficially owned by Radiant."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"(continued from Footnote 2) Elgar International Limited, a British Virgin Islands corporation (\"Elgar International\") is the sole shareholder of Brilliant Dynasty. Brilliant Dynasty will be the sole shareholder of Champion River, Winsave and Radiant upon the completion of the August 2024 Transaction. As such, each of Elger International and Brilliant Dynasty may be deemed to beneficially own the shares of the Issuer's common stock directly held by Champion River, Winsave and Radiant. Chau Hoi Shuen Solina Holly (\"Solina Chau\") is the sole shareholder of each of Pioneer Step, Dvorak International, Skyinvest Associates and Elgar International. As such, Solina Chau may be deemed to beneficially own the shares of the Issuer's common stock directly held by Pioneer Step, Dvorak International, Skyinvest Associates, Champion River, Winsave and Radiant."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Of the total shares beneficially owned following the reported transaction (i) 6,917,783 shares of the Issuer's common stock are directly beneficially owned by Pioneer Step Holdings Limited, a British Virgin Islands corporation (\"Pioneer Step\"), (ii) 420,000 shares of the Issuer's common stock are directly beneficially owned by Dvorak International Limited (\"Dvorak International\"), (iii) 547,858 shares of the Issuer's common stock are directly beneficially owned by Skyinvest Associates Limited (\"Skyinvest Associates\"), (iv) 7,940,937 shares of the Issuer's common stock are directly beneficially owned by Champion River, (v) 3,088,433 shares of the Issuer's common stock are directly beneficially owned by Winsave, and (vi) 379,345 shares of the Issuer's common stock are directly beneficially owned by Radiant."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"(continued from Footnote 2) Elgar International Limited, a British Virgin Islands corporation (\"Elgar International\") is the sole shareholder of Brilliant Dynasty. Brilliant Dynasty will be the sole shareholder of Champion River, Winsave and Radiant upon the completion of the August 2024 Transaction. As such, each of Elger International and Brilliant Dynasty may be deemed to beneficially own the shares of the Issuer's common stock directly held by Champion River, Winsave and Radiant. Chau Hoi Shuen Solina Holly (\"Solina Chau\") is the sole shareholder of each of Pioneer Step, Dvorak International, Skyinvest Associates and Elgar International. As such, Solina Chau may be deemed to beneficially own the shares of the Issuer's common stock directly held by Pioneer Step, Dvorak International, Skyinvest Associates, Champion River, Winsave and Radiant."}],"balance_after":19294356,"source":{"system":"sec-edgar","filing":"0000950170-24-099382","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2032925/000095017024099382/ownership.xml","form_type":"4"}},{"id":1470423,"issuer":{"id":6146,"kind":"organization","name":"Niagen Bioscience, Inc."},"owners":[{"id":25378,"kind":"person","name":"Rubin Steven D","position":1,"cik":"0001381874","reported_name":"Rubin Steven D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-24T21:45:01.000Z","date":"2024-06-20","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Option vests 100% on June 20, 2025."}],"balance_after":20000,"derivative":{"exercise_price":2.71,"exercise_date":"2025-06-20","expiration_date":"2034-06-19","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001628280-24-029653","document":"wk-form4_1719265494.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1381874/000162828024029653/wk-form4_1719265494.xml","form_type":"4"}},{"id":1470419,"issuer":{"id":6146,"kind":"organization","name":"Niagen Bioscience, Inc."},"owners":[{"id":30735,"kind":"person","name":"Patrick Kristin","position":1,"cik":"0001769529","reported_name":"Patrick Kristin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-24T21:44:24.000Z","date":"2024-06-20","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Option vests 100% on June 20, 2025."}],"balance_after":20000,"derivative":{"exercise_price":2.71,"exercise_date":"2025-06-20","expiration_date":"2034-06-19","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001628280-24-029652","document":"wk-form4_1719265458.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1386570/000162828024029652/wk-form4_1719265458.xml","form_type":"4"}},{"id":1470913,"issuer":{"id":6146,"kind":"organization","name":"Niagen Bioscience, Inc."},"owners":[{"id":35199,"kind":"person","name":"Ng Wang Yu Gary","position":1,"cik":"0001896252","reported_name":"Ng Wang Yu Gary","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-24T21:43:39.000Z","date":"2024-06-20","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Option vests 100% on June 20, 2025."}],"balance_after":20000,"derivative":{"exercise_price":2.71,"exercise_date":"2025-06-20","expiration_date":"2034-06-19","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001628280-24-029650","document":"wk-form4_1719265412.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1896252/000162828024029650/wk-form4_1719265412.xml","form_type":"4"}},{"id":1470722,"issuer":{"id":6146,"kind":"organization","name":"Niagen Bioscience, Inc."},"owners":[{"id":35159,"kind":"person","name":"YU Wing Tak Wendy","position":1,"cik":"0001713918","reported_name":"YU Wing Tak Wendy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-24T21:43:00.000Z","date":"2024-06-20","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Option vests 100% on June 20, 2025."}],"balance_after":20000,"derivative":{"exercise_price":2.71,"exercise_date":"2025-06-20","expiration_date":"2034-06-19","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001628280-24-029648","document":"wk-form4_1719265373.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1713918/000162828024029648/wk-form4_1719265373.xml","form_type":"4"}},{"id":1470930,"issuer":{"id":6146,"kind":"organization","name":"Niagen Bioscience, Inc."},"owners":[{"id":35203,"kind":"person","name":"Shahbazi Hamed","position":1,"cik":"0001942711","reported_name":"Shahbazi Hamed","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-24T21:42:03.000Z","date":"2024-06-20","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Option vests 100% on June 20, 2025."}],"balance_after":20000,"derivative":{"exercise_price":2.71,"exercise_date":"2025-06-20","expiration_date":"2034-06-19","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001628280-24-029647","document":"wk-form4_1719265316.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1942711/000162828024029647/wk-form4_1719265316.xml","form_type":"4"}},{"id":1471941,"issuer":{"id":6146,"kind":"organization","name":"Niagen Bioscience, Inc."},"owners":[{"id":35127,"kind":"person","name":"Jaksch Frank L Jr","position":1,"cik":"0001437237","reported_name":"Jaksch Frank L Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-21T22:14:05.000Z","date":"2024-06-20","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Option vests 100% on June 20, 2025."}],"balance_after":20000,"derivative":{"exercise_price":2.71,"exercise_date":"2025-06-20","expiration_date":"2034-06-19","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001628280-24-029397","document":"wk-form4_1719008038.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1437237/000162828024029397/wk-form4_1719008038.xml","form_type":"4"}},{"id":1472269,"issuer":{"id":6146,"kind":"organization","name":"Niagen Bioscience, Inc."},"owners":[{"id":35201,"kind":"person","name":"Cohen Ann","position":1,"cik":"0001923843","reported_name":"Cohen Ann","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-21T22:12:40.000Z","date":"2024-06-20","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Option vests 100% on June 20, 2025."}],"balance_after":20000,"derivative":{"exercise_price":2.71,"exercise_date":"2025-06-20","expiration_date":"2034-06-19","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001628280-24-029395","document":"wk-form4_1719007954.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1923843/000162828024029395/wk-form4_1719007954.xml","form_type":"4"}},{"id":1622076,"issuer":{"id":6146,"kind":"organization","name":"Niagen Bioscience, Inc."},"owners":[{"id":93939,"kind":"person","name":"Gerber Brianna","position":1,"cik":"0001942395","reported_name":"Gerber Brianna","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Options (right to buy)","published_at":"2024-02-24T02:00:40.000Z","date":"2024-02-22","kind":"grant","planned":false,"acquired":true,"shares":213886,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-third of the shares subject to the option shall vest on February 22, 2025 and the remaining shares subject to the option shall vest in a series of 24 equal monthly installments thereafter."}],"balance_after":213886,"derivative":{"exercise_price":1.52,"exercise_date":"2025-02-22","expiration_date":"2034-02-21","underlying":"Common Stock","underlying_shares":213886},"source":{"system":"sec-edgar","filing":"0001628280-24-006725","document":"wk-form4_1708740022.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1386570/000162828024006725/wk-form4_1708740022.xml","form_type":"4"}},{"id":1622347,"issuer":{"id":6146,"kind":"organization","name":"Niagen Bioscience, Inc."},"owners":[{"id":31423,"kind":"person","name":"Fried Robert N","position":1,"cik":"0001417952","reported_name":"Fried Robert N","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Options (right to buy)","published_at":"2024-02-24T01:59:47.000Z","date":"2024-02-22","kind":"grant","planned":false,"acquired":true,"shares":399568,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-third of the shares subject to the option shall vest on February 22, 2025 and the remaining shares subject to the option shall vest in a series of 24 equal monthly installments thereafter."}],"balance_after":399568,"derivative":{"exercise_price":1.52,"exercise_date":"2025-02-22","expiration_date":"2034-02-21","underlying":"Common Stock","underlying_shares":399568},"source":{"system":"sec-edgar","filing":"0001628280-24-006724","document":"wk-form4_1708739974.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1417952/000162828024006724/wk-form4_1708739974.xml","form_type":"4"}},{"id":1723514,"issuer":{"id":6146,"kind":"organization","name":"Niagen Bioscience, Inc."},"owners":[{"id":93939,"kind":"person","name":"Gerber Brianna","position":1,"cik":"0001942395","reported_name":"Gerber Brianna","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-12-04T21:12:33.000Z","date":"2023-12-01","kind":"purchase","planned":false,"acquired":true,"shares":5000,"price":1.41,"value":7050.0,"ownership":{"direct":true},"balance_after":27436,"source":{"system":"sec-edgar","filing":"0001628280-23-040625","document":"wk-form4_1701724341.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1386570/000162828023040625/wk-form4_1701724341.xml","form_type":"4"}},{"id":1785648,"issuer":{"id":6146,"kind":"organization","name":"Niagen Bioscience, Inc."},"owners":[{"id":88135,"kind":"organization","name":"Champion River Ventures Ltd","position":1,"cik":"0001705321","reported_name":"Champion River Ventures Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":88121,"kind":"organization","name":"Prime Tech Global Ltd","position":2,"cik":"0001706084","reported_name":"Prime Tech Global Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":88122,"kind":"organization","name":"Mayspin Management Ltd","position":3,"cik":"0001706083","reported_name":"Mayspin Management Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":109891,"kind":"person","name":"SHING LI KA","position":4,"cik":"0001713623","reported_name":"SHING LI KA","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-09-07T10:23:14.000Z","date":"2023-09-06","kind":"purchase","planned":false,"acquired":true,"shares":3467778,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On September 6, 2023, Alpha Mount International Limited (\"Alpha\") acquired all of the share capital of Winsave Resources Limited (\"Winsave\") and Radiant Treasure Limited (\"Radiant\") from Li Ka Shing (Global) Foundation, a Cayman Islands company limited by guarantee (\"LKSGF\"). Winsave and Radiant beneficially own 3,088,433 Shares and 379,345 Shares, respectively. Alpha acquired Winsave for $1 and the assumption of a loan in the principal amount of $13,048,504.47 from LKSGF in favor of Winsave.  Alpha acquired Radiant for $1 and the assumption of a loan in the principal amount of $1,672,688.07 from LKSGF in favor of Radiant."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 6, 2023, Alpha Mount International Limited (\"Alpha\") acquired all of the share capital of Winsave Resources Limited (\"Winsave\") and Radiant Treasure Limited (\"Radiant\") from Li Ka Shing (Global) Foundation, a Cayman Islands company limited by guarantee (\"LKSGF\"). Winsave and Radiant beneficially own 3,088,433 Shares and 379,345 Shares, respectively. Alpha acquired Winsave for $1 and the assumption of a loan in the principal amount of $13,048,504.47 from LKSGF in favor of Winsave.  Alpha acquired Radiant for $1 and the assumption of a loan in the principal amount of $1,672,688.07 from LKSGF in favor of Radiant."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Of the reported shares (i) 7,940,937  shares of the Issuer's common stock are held directly by Champion River Ventures Limited (\"Champion River\"), (ii) 3,088,433 shares of the Issuer's common stock are held directly by Winsave and (iii) 379,345 shares of the Issuer's common stock are held directly by Radiant. The sole shareholder of Champion River is Prime Tech Global Limited (\"Prime Tech\"), the sole shareholder of Prime Tech is Mayspin Management Limited (\"Mayspin\"), and the sole shareholder of Mayspin is Li Ka Shing. Alpha is the sole shareholder of each of Winsave and Radiant, Apex Dynasty Limited (\"Apex\") is the sole shareholder of Alpha, and Li Ka Shing is the sole shareholder of Apex."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Of the reported shares (i) 7,940,937  shares of the Issuer's common stock are held directly by Champion River Ventures Limited (\"Champion River\"), (ii) 3,088,433 shares of the Issuer's common stock are held directly by Winsave and (iii) 379,345 shares of the Issuer's common stock are held directly by Radiant. The sole shareholder of Champion River is Prime Tech Global Limited (\"Prime Tech\"), the sole shareholder of Prime Tech is Mayspin Management Limited (\"Mayspin\"), and the sole shareholder of Mayspin is Li Ka Shing. Alpha is the sole shareholder of each of Winsave and Radiant, Apex Dynasty Limited (\"Apex\") is the sole shareholder of Alpha, and Li Ka Shing is the sole shareholder of Apex."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Of the reported shares (i) 7,940,937  shares of the Issuer's common stock are held directly by Champion River Ventures Limited (\"Champion River\"), (ii) 3,088,433 shares of the Issuer's common stock are held directly by Winsave and (iii) 379,345 shares of the Issuer's common stock are held directly by Radiant. The sole shareholder of Champion River is Prime Tech Global Limited (\"Prime Tech\"), the sole shareholder of Prime Tech is Mayspin Management Limited (\"Mayspin\"), and the sole shareholder of Mayspin is Li Ka Shing. Alpha is the sole shareholder of each of Winsave and Radiant, Apex Dynasty Limited (\"Apex\") is the sole shareholder of Alpha, and Li Ka Shing is the sole shareholder of Apex."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Of the reported shares (i) 7,940,937  shares of the Issuer's common stock are held directly by Champion River Ventures Limited (\"Champion River\"), (ii) 3,088,433 shares of the Issuer's common stock are held directly by Winsave and (iii) 379,345 shares of the Issuer's common stock are held directly by Radiant. The sole shareholder of Champion River is Prime Tech Global Limited (\"Prime Tech\"), the sole shareholder of Prime Tech is Mayspin Management Limited (\"Mayspin\"), and the sole shareholder of Mayspin is Li Ka Shing. Alpha is the sole shareholder of each of Winsave and Radiant, Apex Dynasty Limited (\"Apex\") is the sole shareholder of Alpha, and Li Ka Shing is the sole shareholder of Apex."}],"balance_after":11408715,"source":{"system":"sec-edgar","filing":"0000899243-23-018667","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1386570/000089924323018667/doc4.xml","form_type":"4"}},{"id":1807062,"issuer":{"id":6146,"kind":"organization","name":"Niagen Bioscience, Inc."},"owners":[{"id":93939,"kind":"person","name":"Gerber Brianna","position":1,"cik":"0001942395","reported_name":"Gerber Brianna","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Unit","published_at":"2023-08-16T01:11:46.000Z","date":"2023-08-12","kind":"exercise","planned":false,"acquired":false,"shares":22436,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"On August 12, 2022, the Reporting Person was awarded RSUs which will be settled in shares of Common Stock when vested."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Vesting of restricted stock units (\"RSUs\") previously granted to the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"RSUs shall vest and be settled in shares of Common Stock in three substantially equal annual installments beginning on August 12, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"RSUs shall vest and be settled in shares of Common Stock in three substantially equal annual installments beginning on August 12, 2023."}],"balance_after":44872,"derivative":{"underlying":"Common Stock","underlying_shares":22436},"source":{"system":"sec-edgar","filing":"0001628280-23-029599","document":"wk-form4_1692148297.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1386570/000162828023029599/wk-form4_1692148297.xml","form_type":"4"}},{"id":1807061,"issuer":{"id":6146,"kind":"organization","name":"Niagen Bioscience, Inc."},"owners":[{"id":93939,"kind":"person","name":"Gerber Brianna","position":1,"cik":"0001942395","reported_name":"Gerber Brianna","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-08-16T01:11:46.000Z","date":"2023-08-12","kind":"exercise","planned":false,"acquired":true,"shares":22436,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Vesting of restricted stock units (\"RSUs\") previously granted to the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 12, 2022, the Reporting Person was awarded RSUs which will be settled in shares of Common Stock when vested."}],"balance_after":22436,"source":{"system":"sec-edgar","filing":"0001628280-23-029599","document":"wk-form4_1692148297.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1386570/000162828023029599/wk-form4_1692148297.xml","form_type":"4"}},{"id":1852357,"issuer":{"id":6146,"kind":"organization","name":"Niagen Bioscience, Inc."},"owners":[{"id":35159,"kind":"person","name":"YU Wing Tak Wendy","position":1,"cik":"0001713918","reported_name":"YU Wing Tak Wendy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-16T21:30:53.000Z","date":"2023-06-15","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Option vests 100% on June 15, 2024."}],"balance_after":20000,"derivative":{"exercise_price":1.67,"exercise_date":"2024-06-15","expiration_date":"2033-06-14","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001628280-23-022542","document":"wk-form4_1686951029.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1713918/000162828023022542/wk-form4_1686951029.xml","form_type":"4"}},{"id":1852776,"issuer":{"id":6146,"kind":"organization","name":"Niagen Bioscience, Inc."},"owners":[{"id":35203,"kind":"person","name":"Shahbazi Hamed","position":1,"cik":"0001942711","reported_name":"Shahbazi Hamed","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-16T21:29:32.000Z","date":"2023-06-15","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Option vests 100% on June 15, 2024."}],"balance_after":20000,"derivative":{"exercise_price":1.67,"exercise_date":"2024-06-15","expiration_date":"2033-06-14","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001628280-23-022539","document":"wk-form4_1686950964.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1942711/000162828023022539/wk-form4_1686950964.xml","form_type":"4"}},{"id":1851624,"issuer":{"id":6146,"kind":"organization","name":"Niagen Bioscience, Inc."},"owners":[{"id":25378,"kind":"person","name":"Rubin Steven D","position":1,"cik":"0001381874","reported_name":"Rubin Steven D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-16T21:28:03.000Z","date":"2023-06-15","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Option vests 100% on June 15, 2024."}],"balance_after":20000,"derivative":{"exercise_price":1.67,"exercise_date":"2024-06-15","expiration_date":"2033-06-14","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001628280-23-022537","document":"wk-form4_1686950874.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1381874/000162828023022537/wk-form4_1686950874.xml","form_type":"4"}},{"id":1851612,"issuer":{"id":6146,"kind":"organization","name":"Niagen Bioscience, Inc."},"owners":[{"id":30735,"kind":"person","name":"Patrick Kristin","position":1,"cik":"0001769529","reported_name":"Patrick Kristin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-16T21:26:43.000Z","date":"2023-06-15","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Option vests 100% on June 15, 2024."}],"balance_after":20000,"derivative":{"exercise_price":1.67,"exercise_date":"2024-06-15","expiration_date":"2033-06-14","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001628280-23-022533","document":"wk-form4_1686950795.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1386570/000162828023022533/wk-form4_1686950795.xml","form_type":"4"}},{"id":1852729,"issuer":{"id":6146,"kind":"organization","name":"Niagen Bioscience, Inc."},"owners":[{"id":35199,"kind":"person","name":"Ng Wang Yu Gary","position":1,"cik":"0001896252","reported_name":"Ng Wang Yu Gary","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-16T21:25:42.000Z","date":"2023-06-15","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Option vests 100% on June 15, 2024."}],"balance_after":20000,"derivative":{"exercise_price":1.67,"exercise_date":"2024-06-15","expiration_date":"2033-06-14","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001628280-23-022530","document":"wk-form4_1686950733.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1896252/000162828023022530/wk-form4_1686950733.xml","form_type":"4"}},{"id":1852746,"issuer":{"id":6146,"kind":"organization","name":"Niagen Bioscience, Inc."},"owners":[{"id":35201,"kind":"person","name":"Cohen Ann","position":1,"cik":"0001923843","reported_name":"Cohen Ann","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-16T21:24:24.000Z","date":"2023-06-15","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Option vests 100% on June 15, 2024."}],"balance_after":20000,"derivative":{"exercise_price":1.67,"exercise_date":"2024-06-15","expiration_date":"2033-06-14","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001628280-23-022525","document":"wk-form4_1686950655.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1923843/000162828023022525/wk-form4_1686950655.xml","form_type":"4"}},{"id":1851970,"issuer":{"id":6146,"kind":"organization","name":"Niagen Bioscience, Inc."},"owners":[{"id":35127,"kind":"person","name":"Jaksch Frank L Jr","position":1,"cik":"0001437237","reported_name":"Jaksch Frank L Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-16T21:23:15.000Z","date":"2023-06-15","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Option vests 100% on June 15, 2024."}],"balance_after":20000,"derivative":{"exercise_price":1.67,"exercise_date":"2024-06-15","expiration_date":"2033-06-14","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001628280-23-022522","document":"wk-form4_1686950586.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1437237/000162828023022522/wk-form4_1686950586.xml","form_type":"4"}},{"id":1857131,"issuer":{"id":6146,"kind":"organization","name":"Niagen Bioscience, Inc."},"owners":[{"id":35127,"kind":"person","name":"Jaksch Frank L Jr","position":1,"cik":"0001437237","reported_name":"Jaksch Frank L Jr","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-13T20:50:09.000Z","date":"2023-06-12","kind":"purchase","planned":false,"acquired":true,"shares":7000,"price":1.69,"value":11830.0,"ownership":{"direct":true},"balance_after":231339,"source":{"system":"sec-edgar","filing":"0001628280-23-021978","document":"wk-form4_1686689397.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1437237/000162828023021978/wk-form4_1686689397.xml","form_type":"4"}},{"id":1871805,"issuer":{"id":6146,"kind":"organization","name":"Niagen Bioscience, Inc."},"owners":[{"id":31423,"kind":"person","name":"Fried Robert N","position":1,"cik":"0001417952","reported_name":"Fried Robert N","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-06-01T20:27:50.000Z","date":"2023-05-31","kind":"purchase","planned":false,"acquired":true,"shares":7000,"price":1.42,"value":9940.0,"ownership":{"direct":false,"nature":"By Fried-Travis Revocable Trust U/A Dated 06/02/1999"},"balance_after":95001,"source":{"system":"sec-edgar","filing":"0001628280-23-020508","document":"wk-form4_1685651259.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1417952/000162828023020508/wk-form4_1685651259.xml","form_type":"4"}},{"id":1874340,"issuer":{"id":6146,"kind":"organization","name":"Niagen Bioscience, Inc."},"owners":[{"id":25378,"kind":"person","name":"Rubin Steven D","position":1,"cik":"0001381874","reported_name":"Rubin Steven D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-05-30T20:13:28.000Z","date":"2023-05-25","kind":"purchase","planned":false,"acquired":true,"shares":7000,"price":1.46,"value":10220.0,"ownership":{"direct":true},"balance_after":7000,"source":{"system":"sec-edgar","filing":"0001628280-23-020112","document":"wk-form4_1685477593.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1381874/000162828023020112/wk-form4_1685477593.xml","form_type":"4"}},{"id":2006735,"issuer":{"id":6146,"kind":"organization","name":"Niagen Bioscience, Inc."},"owners":[{"id":93939,"kind":"person","name":"Gerber Brianna","position":1,"cik":"0001942395","reported_name":"Gerber Brianna","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Options (right to buy)","published_at":"2023-02-17T22:09:27.000Z","date":"2023-02-15","kind":"grant","acquired":true,"shares":163996,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-third of the shares subject to the option shall vest on February 15, 2024 and the remaining shares subject to the option shall vest in a series of 24 equal monthly installments thereafter."}],"balance_after":163996,"derivative":{"exercise_price":1.82,"exercise_date":"2024-02-15","expiration_date":"2033-02-14","underlying":"Common Stock","underlying_shares":163996},"source":{"system":"sec-edgar","filing":"0001628280-23-004092","document":"wf-form4_167667171935135.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1386570/000162828023004092/wf-form4_167667171935135.xml","form_type":"4"}},{"id":2007308,"issuer":{"id":6146,"kind":"organization","name":"Niagen Bioscience, Inc."},"owners":[{"id":31423,"kind":"person","name":"Fried Robert N","position":1,"cik":"0001417952","reported_name":"Fried Robert N","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Cheif Executive Officer"}}],"security":"Employee Stock Options (right to buy)","published_at":"2023-02-17T22:05:37.000Z","date":"2023-02-15","kind":"grant","acquired":true,"shares":306366,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-third of the shares subject to the option shall vest on February 15, 2024 and the remaining shares subject to the option shall vest in a series of 24 equal monthly installments thereafter."}],"balance_after":306366,"derivative":{"exercise_price":1.82,"exercise_date":"2024-02-15","expiration_date":"2033-02-14","underlying":"Common Stock","underlying_shares":306366},"source":{"system":"sec-edgar","filing":"0001628280-23-004086","document":"wf-form4_167667149838499.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1417952/000162828023004086/wf-form4_167667149838499.xml","form_type":"4"}},{"id":2147163,"issuer":{"id":6146,"kind":"organization","name":"Niagen Bioscience, Inc."},"owners":[{"id":31423,"kind":"person","name":"Fried Robert N","position":1,"cik":"0001417952","reported_name":"Fried Robert N","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Cheif Executive Officer"}}],"security":"Common Stock","published_at":"2022-10-04T00:17:32.000Z","date":"2022-09-30","kind":"purchase","acquired":true,"shares":80000,"price":1.25,"value":100000.0,"ownership":{"direct":true},"balance_after":972314,"source":{"system":"sec-edgar","filing":"0001628280-22-025915","document":"wf-form4_166484261652383.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1417952/000162828022025915/wf-form4_166484261652383.xml","form_type":"4"}},{"id":2147524,"issuer":{"id":6146,"kind":"organization","name":"Niagen Bioscience, Inc."},"owners":[{"id":88129,"kind":"person","name":"Chau Hoi Shuen Solina Holly","position":1,"cik":"0001687026","reported_name":"Chau Hoi Shuen Solina Holly","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":88130,"kind":"organization","name":"Pioneer Step Holdings Ltd","position":2,"cik":"0001705335","reported_name":"Pioneer Step Holdings Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":88131,"kind":"organization","name":"Dvorak International Ltd","position":3,"cik":"0001796851","reported_name":"Dvorak International Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-10-03T08:34:46.000Z","date":"2022-09-30","kind":"purchase","acquired":true,"shares":960000,"price":1.25,"value":1200000.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Pioneer Step Holdings Limited (\"Pioneer Step\") has agreed to purchase 960,000  shares of the Issuer's common stock pursuant to the Securities Purchase Agreement dated September 30, 2022 by and among the Issuer, Pioneer Step and other purchasers named therein."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Of the total shares beneficially owned following the reported transaction (i) 6,917,783  shares of the Issuer's common stock are directly beneficially owned by Pioneer Step, (ii) 420,000 shares of the Issuer's common stock are directly beneficially owned by Dvorak International Limited (\"Dvorak International\"), and (iii) 547,858 shares of the Issuer's common stock are directly beneficially owned by Skyinvest Associates Limited (\"Skyinvest Associates\").  Chau Hoi Shuen Solina Holly (\"Solina Chau\") is the sole shareholder of each of Pioneer Step, Dvorak International, and Skyinvest Associates."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"(continued from Footnote 2) As such, Solina Chau may be deemed to beneficially own the shares of the Issuer's common stock directly held by Pioneer Step, Dvorak International and Skyinvest Associates. Solina Chau disclaims Section 16 beneficial ownership of the securities held by each of Pioneer Step, Dvorak International and Skyinvest Associes, except to the extent of her pecuniary interest therein, if any."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Of the total shares beneficially owned following the reported transaction (i) 6,917,783  shares of the Issuer's common stock are directly beneficially owned by Pioneer Step, (ii) 420,000 shares of the Issuer's common stock are directly beneficially owned by Dvorak International Limited (\"Dvorak International\"), and (iii) 547,858 shares of the Issuer's common stock are directly beneficially owned by Skyinvest Associates Limited (\"Skyinvest Associates\").  Chau Hoi Shuen Solina Holly (\"Solina Chau\") is the sole shareholder of each of Pioneer Step, Dvorak International, and Skyinvest Associates."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"(continued from Footnote 2) As such, Solina Chau may be deemed to beneficially own the shares of the Issuer's common stock directly held by Pioneer Step, Dvorak International and Skyinvest Associates. Solina Chau disclaims Section 16 beneficial ownership of the securities held by each of Pioneer Step, Dvorak International and Skyinvest Associes, except to the extent of her pecuniary interest therein, if any."}],"balance_after":7885641,"source":{"system":"sec-edgar","filing":"0000899243-22-032394","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1796851/000089924322032394/doc4.xml","form_type":"4"}},{"id":2187157,"issuer":{"id":6146,"kind":"organization","name":"Niagen Bioscience, Inc."},"owners":[{"id":35203,"kind":"person","name":"Shahbazi Hamed","position":1,"cik":"0001942711","reported_name":"Shahbazi Hamed","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-08-13T01:11:56.000Z","date":"2022-08-09","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in three substantially equal annual installments beginning on August 9, 2023."}],"balance_after":40000,"derivative":{"exercise_price":1.92,"exercise_date":"2023-08-09","expiration_date":"2032-08-08","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001628280-22-022759","document":"wf-form4_166035310008029.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1942711/000162828022022759/wf-form4_166035310008029.xml","form_type":"4"}},{"id":2186665,"issuer":{"id":6146,"kind":"organization","name":"Niagen Bioscience, Inc."},"owners":[{"id":93939,"kind":"person","name":"Gerber Brianna","position":1,"cik":"0001942395","reported_name":"Gerber Brianna","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Finance / Interim CFO"}}],"security":"Restricted Stock Unit","published_at":"2022-08-13T01:06:34.000Z","date":"2022-08-12","kind":"grant","acquired":true,"shares":67308,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"On August 12, 2022, the reporting person was awarded Restricted Stock Units (\"RSUs\") which will be settled in shares of Common Stock when vested."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"RSUs shall vest and be settled in shares of Common Stock in three substantially equal annual installments beginning on August 12, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"RSUs shall vest and be settled in shares of Common Stock in three substantially equal annual installments beginning on August 12, 2023."}],"balance_after":67308,"derivative":{"underlying":"Common Stock","underlying_shares":67308},"source":{"system":"sec-edgar","filing":"0001628280-22-022756","document":"wf-form4_166035275685057.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1386570/000162828022022756/wf-form4_166035275685057.xml","form_type":"4"}},{"id":2186664,"issuer":{"id":6146,"kind":"organization","name":"Niagen Bioscience, Inc."},"owners":[{"id":93939,"kind":"person","name":"Gerber Brianna","position":1,"cik":"0001942395","reported_name":"Gerber Brianna","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Finance / Interim CFO"}}],"security":"Employee Stock Options (right to buy)","published_at":"2022-08-13T01:06:34.000Z","date":"2022-08-12","kind":"grant","acquired":true,"shares":100460,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-third of the shares subject to the option shall vest on August 12, 2023 and the remaining shares subject to the option shall vest in a series of 24 equal monthly installments thereafter."}],"balance_after":100460,"derivative":{"exercise_price":1.69,"exercise_date":"2023-08-12","expiration_date":"2032-08-11","underlying":"Common Stock","underlying_shares":100460},"source":{"system":"sec-edgar","filing":"0001628280-22-022756","document":"wf-form4_166035275685057.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1386570/000162828022022756/wf-form4_166035275685057.xml","form_type":"4"}},{"id":2186796,"issuer":{"id":6146,"kind":"organization","name":"Niagen Bioscience, Inc."},"owners":[{"id":80172,"kind":"person","name":"FARR KEVIN M","position":1,"cik":"0001194262","reported_name":"FARR KEVIN M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Restricted Stock Unit","published_at":"2022-08-12T21:09:23.000Z","date":"2022-08-12","kind":"grant","acquired":true,"shares":89189,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On August 12, 2022, the Reporting Person was awarded Restricted Stock Units (\"RSUs\") in connection with the Reporting Person's transition services to the Issuer and the related consulting agreement with the Reporting Person (the \"Consultant Agreement\") effective August 13, 2022.  The reporting person was terminated as the Chief Financial Officer of the Issuer effective August 12, 2022."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"RSUs shall vest and be settled in shares of Common Stock upon the earlier of the expiration of the Consultant Agreement, which is expected to be on or around November 11, 2022, or the earlier termination of the Consultant Agreement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"RSUs shall vest and be settled in shares of Common Stock upon the earlier of the expiration of the Consultant Agreement, which is expected to be on or around November 11, 2022, or the earlier termination of the Consultant Agreement."}],"balance_after":89189,"derivative":{"underlying":"Common Stock","underlying_shares":89189},"source":{"system":"sec-edgar","filing":"0001628280-22-022757","document":"wf-form4_166035294656633.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1194262/000162828022022757/wf-form4_166035294656633.xml","form_type":"4"}},{"id":2225473,"issuer":{"id":6146,"kind":"organization","name":"Niagen Bioscience, Inc."},"owners":[{"id":35159,"kind":"person","name":"YU Wing Tak Wendy","position":1,"cik":"0001713918","reported_name":"YU Wing Tak Wendy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-22T01:17:18.000Z","date":"2022-06-16","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Option vests 100% on June 16, 2023."}],"balance_after":20000,"derivative":{"exercise_price":1.64,"exercise_date":"2023-06-16","expiration_date":"2032-06-15","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001628280-22-017735","document":"wf-form4_165586062300607.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1713918/000162828022017735/wf-form4_165586062300607.xml","form_type":"4"}},{"id":2225053,"issuer":{"id":6146,"kind":"organization","name":"Niagen Bioscience, Inc."},"owners":[{"id":25378,"kind":"person","name":"Rubin Steven D","position":1,"cik":"0001381874","reported_name":"Rubin Steven D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-21T23:10:27.000Z","date":"2022-06-16","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Option vests 100% on June 16, 2023."}],"balance_after":20000,"derivative":{"exercise_price":1.64,"exercise_date":"2023-06-16","expiration_date":"2032-06-15","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001628280-22-017724","document":"wf-form4_165585300854193.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1381874/000162828022017724/wf-form4_165585300854193.xml","form_type":"4"}},{"id":2225776,"issuer":{"id":6146,"kind":"organization","name":"Niagen Bioscience, Inc."},"owners":[{"id":35201,"kind":"person","name":"Cohen Ann","position":1,"cik":"0001923843","reported_name":"Cohen Ann","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-21T22:24:58.000Z","date":"2022-06-16","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Option vests 100% on June 16, 2023."}],"balance_after":20000,"derivative":{"exercise_price":1.64,"exercise_date":"2023-06-16","expiration_date":"2032-06-15","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001628280-22-017717","document":"wf-form4_165585028468206.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1923843/000162828022017717/wf-form4_165585028468206.xml","form_type":"4"}},{"id":2225044,"issuer":{"id":6146,"kind":"organization","name":"Niagen Bioscience, Inc."},"owners":[{"id":30735,"kind":"person","name":"Patrick Kristin","position":1,"cik":"0001769529","reported_name":"Patrick Kristin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-21T22:23:32.000Z","date":"2022-06-16","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Option vests 100% on June 16, 2023."}],"balance_after":20000,"derivative":{"exercise_price":1.64,"exercise_date":"2023-06-16","expiration_date":"2032-06-15","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001628280-22-017715","document":"wf-form4_165585019790330.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1386570/000162828022017715/wf-form4_165585019790330.xml","form_type":"4"}},{"id":2225769,"issuer":{"id":6146,"kind":"organization","name":"Niagen Bioscience, Inc."},"owners":[{"id":35199,"kind":"person","name":"Ng Wang Yu Gary","position":1,"cik":"0001896252","reported_name":"Ng Wang Yu Gary","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-21T22:22:11.000Z","date":"2022-06-16","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Option vests 100% on June 16, 2023."}],"balance_after":20000,"derivative":{"exercise_price":1.64,"exercise_date":"2023-06-16","expiration_date":"2032-06-15","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001628280-22-017713","document":"wf-form4_165585011423542.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1896252/000162828022017713/wf-form4_165585011423542.xml","form_type":"4"}},{"id":2225517,"issuer":{"id":6146,"kind":"organization","name":"Niagen Bioscience, Inc."},"owners":[{"id":88129,"kind":"person","name":"Chau Hoi Shuen Solina Holly","position":1,"cik":"0001687026","reported_name":"Chau Hoi Shuen Solina Holly","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":88130,"kind":"organization","name":"Pioneer Step Holdings Ltd","position":2,"cik":"0001705335","reported_name":"Pioneer Step Holdings Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":88131,"kind":"organization","name":"Dvorak International Ltd","position":3,"cik":"0001796851","reported_name":"Dvorak International Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-06-21T08:02:03.000Z","date":"2022-06-16","kind":"purchase","acquired":true,"shares":60037,"price":1.6636,"value":99877.5532,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Skyinvest Associates Limited (\"Skyinvest Associates\") acquired 60,037 shares of the Issuer's common stock in open market purchases on June 16, 2022."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Of the total shares beneficially owned following the reported transaction (i) 5,957,783 shares of the Issuer's common stock are held directly by Pioneer Step Holdings Limited (\"Pioneer Step\"), (ii) 420,000 shares of the Issuer's common stock are held directly by Dvorak International Limited (\"Dvorak International\"), and (iii) 547,858 shares of the Issuer's common stock are held directly by Skyinvest Associates. Chau Hoi Shuen Solina Holly (\"Solina Chau\") is the sole shareholder of each of Pioneer Step and Dvorak International, and Skyinvest Associates is wholly-owned by Solina Chau through intermediate entities that are directly or indirectly wholly-owned by Solina Chau."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"(continued from Footnote 2) As such, Solina Chau may be deemed to beneficially own the shares of the Issuer's common stock directly held by Pioneer Step, Dvorak International and Skyinvest Associates. Solina Chau disclaims Section 16 beneficial ownership of the securities held by each of Pioneer Step, Dvorak International and Skyinvest Associates, except to the extent of her pecuniary interest therein, if any."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Of the total shares beneficially owned following the reported transaction (i) 5,957,783 shares of the Issuer's common stock are held directly by Pioneer Step Holdings Limited (\"Pioneer Step\"), (ii) 420,000 shares of the Issuer's common stock are held directly by Dvorak International Limited (\"Dvorak International\"), and (iii) 547,858 shares of the Issuer's common stock are held directly by Skyinvest Associates. Chau Hoi Shuen Solina Holly (\"Solina Chau\") is the sole shareholder of each of Pioneer Step and Dvorak International, and Skyinvest Associates is wholly-owned by Solina Chau through intermediate entities that are directly or indirectly wholly-owned by Solina Chau."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"(continued from Footnote 2) As such, Solina Chau may be deemed to beneficially own the shares of the Issuer's common stock directly held by Pioneer Step, Dvorak International and Skyinvest Associates. Solina Chau disclaims Section 16 beneficial ownership of the securities held by each of Pioneer Step, Dvorak International and Skyinvest Associates, except to the extent of her pecuniary interest therein, if any."}],"balance_after":6925641,"source":{"system":"sec-edgar","filing":"0000899243-22-023253","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1796851/000089924322023253/doc4.xml","form_type":"4"}},{"id":2294563,"issuer":{"id":6146,"kind":"organization","name":"Niagen Bioscience, Inc."},"owners":[{"id":30735,"kind":"person","name":"Patrick Kristin","position":1,"cik":"0001769529","reported_name":"Patrick Kristin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-04-20T00:27:47.000Z","date":"2022-04-15","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in three substantially equal annual installments beginning on April 15, 2023."}],"balance_after":40000,"derivative":{"exercise_price":2.14,"exercise_date":"2023-04-15","expiration_date":"2032-04-14","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001628280-22-009591","document":"wf-form4_165041444722067.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1386570/000162828022009591/wf-form4_165041444722067.xml","form_type":"4"}},{"id":2294937,"issuer":{"id":6146,"kind":"organization","name":"Niagen Bioscience, Inc."},"owners":[{"id":35201,"kind":"person","name":"Cohen Ann","position":1,"cik":"0001923843","reported_name":"Cohen Ann","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-04-20T00:23:48.000Z","date":"2022-04-15","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in three substantially equal annual installments beginning on April 15, 2023."}],"balance_after":40000,"derivative":{"exercise_price":2.14,"exercise_date":"2023-04-15","expiration_date":"2032-04-14","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001628280-22-009589","document":"wf-form4_165041421126805.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1923843/000162828022009589/wf-form4_165041421126805.xml","form_type":"4"}},{"id":2330577,"issuer":{"id":6146,"kind":"organization","name":"Niagen Bioscience, Inc."},"owners":[{"id":31423,"kind":"person","name":"Fried Robert N","position":1,"cik":"0001417952","reported_name":"Fried Robert N","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2022-03-16T23:28:43.000Z","date":"2022-03-16","kind":"purchase","acquired":true,"shares":25000,"price":2.16,"value":54000.0,"ownership":{"direct":false,"nature":"By Fried-Travis Revocable Trust U/A Dated 06/02/1999"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The weighted average purchase price for the transaction reported was $2.16, and the range of prices were between $2.14 and $2.16, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased at each separate price within the range above will be provided."}],"balance_after":88001,"source":{"system":"sec-edgar","filing":"0001628280-22-006443","document":"wf-form4_164747330857843.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1417952/000162828022006443/wf-form4_164747330857843.xml","form_type":"4"}},{"id":2382076,"issuer":{"id":6146,"kind":"organization","name":"Niagen Bioscience, Inc."},"owners":[{"id":35127,"kind":"person","name":"Jaksch Frank L Jr","position":1,"cik":"0001437237","reported_name":"Jaksch Frank L Jr","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EXECUTIVE CHAIRMAN OF BOARD"}}],"security":"Employee Stock Options (right to buy)","published_at":"2022-02-22T22:31:01.000Z","date":"2022-02-17","kind":"grant","acquired":true,"shares":107805,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"One-third of the shares subject to the option shall vest on February 17, 2023 and the remaining shares subject to the option shall vest in a series of 24 equal monthly installments thereafter."}],"balance_after":107805,"derivative":{"exercise_price":2.67,"exercise_date":"2023-02-17","expiration_date":"2032-02-16","underlying":"Common Stock","underlying_shares":107805},"source":{"system":"sec-edgar","filing":"0001628280-22-003374","document":"wf-form4_164556903170946.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1437237/000162828022003374/wf-form4_164556903170946.xml","form_type":"4"}},{"id":2382047,"issuer":{"id":6146,"kind":"organization","name":"Niagen Bioscience, Inc."},"owners":[{"id":31423,"kind":"person","name":"Fried Robert N","position":1,"cik":"0001417952","reported_name":"Fried Robert N","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Employee Stock Options (right to buy)","published_at":"2022-02-22T22:28:55.000Z","date":"2022-02-17","kind":"grant","acquired":true,"shares":240448,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-third of the shares subject to the option shall vest on February 17, 2023 and the remaining shares subject to the option shall vest in a series of 24 equal monthly installments thereafter."}],"balance_after":240448,"derivative":{"exercise_price":2.67,"exercise_date":"2023-02-17","expiration_date":"2032-02-16","underlying":"Common Stock","underlying_shares":240448},"source":{"system":"sec-edgar","filing":"0001628280-22-003371","document":"wf-form4_164556891215777.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1417952/000162828022003371/wf-form4_164556891215777.xml","form_type":"4"}},{"id":2381845,"issuer":{"id":6146,"kind":"organization","name":"Niagen Bioscience, Inc."},"owners":[{"id":80172,"kind":"person","name":"FARR KEVIN M","position":1,"cik":"0001194262","reported_name":"FARR KEVIN M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Employee Stock Options (right to buy)","published_at":"2022-02-22T17:29:54.000Z","date":"2022-02-17","kind":"grant","acquired":true,"shares":122374,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"One-third of the shares subject to the option shall vest on February 17, 2023 and the remaining shares subject to the option shall vest in a series of 24 equal monthly installments thereafter."}],"balance_after":122374,"derivative":{"exercise_price":2.67,"exercise_date":"2023-02-17","expiration_date":"2032-02-16","underlying":"Common Stock","underlying_shares":122374},"source":{"system":"sec-edgar","filing":"0001628280-22-003372","document":"wf-form4_164556897219267.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1194262/000162828022003372/wf-form4_164556897219267.xml","form_type":"4"}},{"id":2473824,"issuer":{"id":6146,"kind":"organization","name":"Niagen Bioscience, Inc."},"owners":[{"id":35199,"kind":"person","name":"Ng Wang Yu Gary","position":1,"cik":"0001896252","reported_name":"Ng Wang Yu Gary","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-12-14T23:06:48.000Z","date":"2021-12-13","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in three substantially equal annual installments beginning on December 13, 2022."}],"balance_after":40000,"derivative":{"exercise_price":4.24,"exercise_date":"2022-12-13","expiration_date":"2031-12-12","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001628280-21-025061","document":"wf-form4_163952319561269.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1896252/000162828021025061/wf-form4_163952319561269.xml","form_type":"4"}},{"id":2488201,"issuer":{"id":6146,"kind":"organization","name":"Niagen Bioscience, Inc."},"owners":[{"id":19359,"kind":"person","name":"Levy Caroline S","position":1,"cik":"0001820042","reported_name":"Levy Caroline S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-12-02T21:45:41.000Z","date":"2021-12-01","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in three substantially equal annual installments beginning on December 1, 2022."}],"balance_after":40000,"derivative":{"exercise_price":4.53,"exercise_date":"2022-12-01","expiration_date":"2031-11-30","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001628280-21-024444","document":"wf-form4_163848152738878.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1386570/000162828021024444/wf-form4_163848152738878.xml","form_type":"4"}},{"id":2658433,"issuer":{"id":6146,"kind":"organization","name":"Niagen Bioscience, Inc."},"owners":[{"id":111069,"kind":"person","name":"Baxter Jeff","position":1,"cik":"0001615941","reported_name":"Baxter Jeff","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2021-06-22T21:28:05.000Z","date":"2021-06-17","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options vest 100% on June 17, 2022"}],"balance_after":20000,"derivative":{"exercise_price":9.99,"exercise_date":"2022-06-17","expiration_date":"2031-06-16","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001628280-21-012676","document":"wf-form4_162439725270272.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1386570/000162828021012676/wf-form4_162439725270272.xml","form_type":"4"}},{"id":2658476,"issuer":{"id":6146,"kind":"organization","name":"Niagen Bioscience, Inc."},"owners":[{"id":25378,"kind":"person","name":"Rubin Steven D","position":1,"cik":"0001381874","reported_name":"Rubin Steven D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2021-06-22T21:27:03.000Z","date":"2021-06-17","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options vest 100% on June 17, 2022"}],"balance_after":20000,"derivative":{"exercise_price":9.99,"exercise_date":"2022-06-17","expiration_date":"2031-06-16","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001628280-21-012673","document":"wf-form4_162439717162695.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1381874/000162828021012673/wf-form4_162439717162695.xml","form_type":"4"}},{"id":2658893,"issuer":{"id":6146,"kind":"organization","name":"Niagen Bioscience, Inc."},"owners":[{"id":35159,"kind":"person","name":"YU Wing Tak Wendy","position":1,"cik":"0001713918","reported_name":"YU Wing Tak Wendy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2021-06-22T21:23:52.000Z","date":"2021-06-17","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options vest 100% on June 17, 2022"}],"balance_after":20000,"derivative":{"exercise_price":9.99,"exercise_date":"2022-06-17","expiration_date":"2031-06-16","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001628280-21-012666","document":"wf-form4_162439695761613.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1713918/000162828021012666/wf-form4_162439695761613.xml","form_type":"4"}},{"id":2658720,"issuer":{"id":6146,"kind":"organization","name":"Niagen Bioscience, Inc."},"owners":[{"id":31436,"kind":"person","name":"GUSTAFSON KURT A","position":1,"cik":"0001462354","reported_name":"GUSTAFSON KURT A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2021-06-22T21:21:42.000Z","date":"2021-06-17","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options vest 100% on June 17, 2022"}],"balance_after":20000,"derivative":{"exercise_price":9.99,"exercise_date":"2022-06-17","expiration_date":"2031-06-16","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001628280-21-012665","document":"wf-form4_162439684890561.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1462354/000162828021012665/wf-form4_162439684890561.xml","form_type":"4"}},{"id":2658892,"issuer":{"id":6146,"kind":"organization","name":"Niagen Bioscience, Inc."},"owners":[{"id":138004,"kind":"person","name":"LAU Tsz Ho Tony","position":1,"cik":"0001714259","reported_name":"LAU Tsz Ho Tony","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2021-06-22T17:27:22.000Z","date":"2021-06-17","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options vest 100% on June 17, 2022"}],"balance_after":20000,"derivative":{"exercise_price":9.99,"exercise_date":"2022-06-17","expiration_date":"2031-06-16","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001628280-21-012674","document":"wf-form4_162439720955892.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714259/000162828021012674/wf-form4_162439720955892.xml","form_type":"4"}},{"id":2658611,"issuer":{"id":6146,"kind":"organization","name":"Niagen Bioscience, Inc."},"owners":[{"id":137998,"kind":"person","name":"BLOCK STEPHEN A","position":1,"cik":"0001183721","reported_name":"BLOCK STEPHEN A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2021-06-22T17:25:39.000Z","date":"2021-06-17","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options vest 100% on June 17, 2022"}],"balance_after":20000,"derivative":{"exercise_price":9.99,"exercise_date":"2022-06-17","expiration_date":"2031-06-16","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001628280-21-012669","document":"wf-form4_162439709292333.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1183721/000162828021012669/wf-form4_162439709292333.xml","form_type":"4"}},{"id":2710200,"issuer":{"id":6146,"kind":"organization","name":"Niagen Bioscience, Inc."},"owners":[{"id":31423,"kind":"person","name":"Fried Robert N","position":1,"cik":"0001417952","reported_name":"Fried Robert N","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2021-05-17T12:30:11.000Z","date":"2021-05-13","kind":"purchase","acquired":true,"shares":10000,"price":6.65,"value":66500.0,"ownership":{"direct":false,"nature":"By Fried-Travis Revocable Trust U/A Dated 06/02/1999"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The weighted average purchase price for the transaction reported was $6.65, and the range of prices were between $6.64 and $6.66.  Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased at each separate price will be provided."}],"balance_after":63001,"source":{"system":"sec-edgar","filing":"0001415889-21-002499","document":"form4-05172021_080502.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1417952/000141588921002499/form4-05172021_080502.xml","form_type":"4"}},{"id":2763796,"issuer":{"id":6146,"kind":"organization","name":"Niagen Bioscience, Inc."},"owners":[{"id":31423,"kind":"person","name":"Fried Robert N","position":1,"cik":"0001417952","reported_name":"Fried Robert N","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2021-04-01T23:24:46.000Z","date":"2020-04-17","kind":"gift","acquired":false,"shares":500000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On April 17, 2020, the Reporting Person transferred an aggregate of 500,000 shares to trusts established for the benefit of his children as follows:  250,000 shares to US Trust Company of Delaware Trustee of The Benjamin A Fried 2020 Irrevocable Trust dated 02/26/2020 and 250,000 shares to US Trust Company of Delaware Trustee of The Jeremy W Fried 2020 Irrevocable Trust dated 02/26/2020."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"1,000 shares held by the Reporting Person were inadvertently reported on a prior Form 4 filing as held directly.  Instead, the shares are held by the Reporting Person indirectly in the name of the Fried-Travis Revocable Trust U/A Dated 06/02/1999."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"9,753 shares held by the Reporting Person were inadvertently reported on prior Form 4 filings as held directly.  Instead, the shares are held by the Reporting Person indirectly in the name of Fried Films Profit Sharing."}],"balance_after":882561,"source":{"system":"sec-edgar","filing":"0001415889-21-001778","document":"form4-04012021_040432.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1417952/000141588921001778/form4-04012021_040432.xml","form_type":"4"}},{"id":2781938,"issuer":{"id":6146,"kind":"organization","name":"Niagen Bioscience, Inc."},"owners":[{"id":35127,"kind":"person","name":"Jaksch Frank L Jr","position":1,"cik":"0001437237","reported_name":"Jaksch Frank L Jr","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EXECUTIVE CHAIRMAN OF BOARD"}}],"security":"Employee Stock Options (right to buy)","published_at":"2021-03-17T22:46:15.000Z","date":"2021-03-15","kind":"grant","acquired":true,"shares":25072,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options vest 33% on March 15, 2022 and thereafter 1/36th vest each month."}],"balance_after":25072,"derivative":{"exercise_price":11.83,"exercise_date":"2022-03-15","expiration_date":"2031-03-14","underlying":"Common Stock","underlying_shares":25072},"source":{"system":"sec-edgar","filing":"0001415889-21-001550","document":"form4-03172021_030304.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1437237/000141588921001550/form4-03172021_030304.xml","form_type":"4"}},{"id":2781860,"issuer":{"id":6146,"kind":"organization","name":"Niagen Bioscience, Inc."},"owners":[{"id":31423,"kind":"person","name":"Fried Robert N","position":1,"cik":"0001417952","reported_name":"Fried Robert N","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Employee Stock Options (right to buy)","published_at":"2021-03-17T22:43:25.000Z","date":"2021-03-15","kind":"grant","acquired":true,"shares":55921,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options vest 33% on March 15, 2022 and thereafter 1/36th vest each month."}],"balance_after":55921,"derivative":{"exercise_price":11.83,"exercise_date":"2022-03-15","expiration_date":"2031-03-14","underlying":"Common Stock","underlying_shares":55921},"source":{"system":"sec-edgar","filing":"0001415889-21-001547","document":"form4-03172021_030338.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1417952/000141588921001547/form4-03172021_030338.xml","form_type":"4"}},{"id":2783125,"issuer":{"id":6146,"kind":"organization","name":"Niagen Bioscience, Inc."},"owners":[{"id":95743,"kind":"person","name":"Harrington Lisa Hatton","position":1,"cik":"0001850211","reported_name":"Harrington Lisa Hatton","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"GENERAL COUNSEL"}}],"security":"Employee Stock Options (right to buy)","published_at":"2021-03-17T18:49:51.000Z","date":"2021-03-15","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options vest 33% on March 15, 2022 and thereafter 1/36th vest each month."}],"balance_after":15000,"derivative":{"exercise_price":11.83,"exercise_date":"2022-03-15","expiration_date":"2031-03-14","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001415889-21-001554","document":"form4-03172021_030321.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1850211/000141588921001554/form4-03172021_030321.xml","form_type":"4"}},{"id":2781492,"issuer":{"id":6146,"kind":"organization","name":"Niagen Bioscience, Inc."},"owners":[{"id":80172,"kind":"person","name":"FARR KEVIN M","position":1,"cik":"0001194262","reported_name":"FARR KEVIN M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Employee Stock Options (right to buy)","published_at":"2021-03-17T18:47:57.000Z","date":"2021-03-15","kind":"grant","acquired":true,"shares":28461,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options vest 33% on March 15, 2022 and thereafter 1/36th vest each month."}],"balance_after":28461,"derivative":{"exercise_price":11.83,"exercise_date":"2022-03-15","expiration_date":"2031-03-14","underlying":"Common Stock","underlying_shares":28461},"source":{"system":"sec-edgar","filing":"0001415889-21-001552","document":"form4-03172021_030343.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1194262/000141588921001552/form4-03172021_030343.xml","form_type":"4"}}],"next_cursor":"2021-03-17T18:47:57.000000Z,2781492"}